Targeted degradation of the oncogenic phosphatase SHP2
V. Vemulapalli, K. A. Donovan, T. Seegar, J. M. Rogers, M. Bae, R. Lumpkin, R. Cao, M. Henke, E. S. Fischer, G. Cuny, S. C. Blacklow
This paper develops a SHP2 PROTAC that degrades SHP2 in leukemic cells, inhibits MAPK signaling, and suppresses cancer growth.
bioRxiv · Jun 2, 2021 · PreprintBiochemistry